Jessica Khoury
Endocrinology, Diabetes & Metabolism · Saint Charles, MDNPI 1265042733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,805 and has fallen 74.1% since, to $468 in 2025.
Across 80 payments — averaging $64.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$607
- E.r. Squibb & Sons, L.L.C.$530
- Sanofi-aventis U.S. LLC$444
- Gilead$326
- GSK$223
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,150100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 18 | $1,092 |
| AstraZeneca(2 entities) | 11 | $607 |
| E.r. Squibb & Sons, L.L.C. | 5 | $530 |
| Sanofi-aventis U.S. LLC | 6 | $444 |
| Gilead | 3 | $326 |
| GSK | 2 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $207 |
| Dexcom, Inc. | 3 | $202 |
| Amgen | 1 | $149 |
| AbbVie | 2 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $128 |
| Beigene USA, Inc. | 1 | $125 |
| Bristol Myers Squibb | 1 | $125 |
| Eisai Inc. | 1 | $120 |
| Lilly USA, LLC | 5 | $116 |
| Mirati Therapeutics, Inc. | 1 | $112 |
| Bayer | 1 | $108 |
| Madrigal Pharmaceuticals | 2 | $61 |
| Echosens North America, Inc. | 1 | $53 |
| Tandem Diabetes Care, Inc. | 1 | $51 |
| Novo Nordisk | 2 | $48 |
| Corcept Therapeutics | 2 | $47 |
| Insulet Corporation | 1 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $16 |
| Cequr Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,150 in reported general payments places this provider in the 75th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 15 | $909 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Saint Charles
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.